Share on LinkedInShare on LinkedIn

ARTICLE · 23 APRIL 2025

Public Interest Prevails – Roche Denied Injunction In Patent Dispute

RNA Technology and IP Attorneys
RNA Technology and IP Attorneys
Contributor
RNA Technology and IP Attorneys

RNA Technology and IP Attorneys

RNA’s business had its roots in trademarks before it branched into other forms of Intellectual...

View firm profile
Explore more from RNA Technology and IP Attorneys

F. Hoffmann-La Roche AG (Roche) brought a Patent infringement case, at the Delhi High Court, against Natco Pharma Limited (Natco).

IndiaIntellectual Property

CS(COMM) 567/2024, Delhi High Court.

Background

F. Hoffmann-La Roche AG (Roche) brought a Patent infringement case, at the Delhi High Court, against Natco Pharma Limited (Natco). The claim of Rochhe was based on infringement of its Patent for a compound Risdiplam marketed under the brand name EVRYSDI® used in the treatment of Spinal Muscular Atrophy (SMA). Risdiplam is an oral prescription medicine indicated for the treatment of SMA in patients two months of age or older. The note analyses the arguments of the parties, two intervenors that raised public interest issues and Court's decision on interim injunction being sought by Roche.

Roche's case and contentions

  1. Admission of Infringement: Roche argued that Natco Pharma Limited admitted to the infringement by stating that they were in the process of launching Risdiplam.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from